Kuickresearch::Industry News

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

USA Bispecific Antibodies Sales Q1 2024

Release Date: 16 May 2024

 

During first 3 months of 2024 bispecific antibodies sales in USA surpased USD 1.5 Billion and accounted for dominant share in global bispecific antibodies sales.

Read More


Vabysmo Sales Q1 2024

Release Date: 16 May 2024

 

Vabysmo saswittnesed postive outlook  during first quarter of 2024. Vabysmo  sales surpassed USD 900 Million accounting for more than 35% of global bispecific antibodi...

Read More


Hemlibra Sales Q1 2024

Release Date: 16 May 2024

 

Hemlibra sales surpased USD 1 Billion during first 3 months of 2024.Hemlibra accounted for more than 40% of global bispecific antibodies sales during first 3 months of 2024.

Read More


Bispecific Antibodies Sales More Than USD 2 Billion In Q1 2024

Release Date: 16 May 2024

Global Bispecific Antibodies sales surpassed USD 2.40 Billion during  Q1 2024. More than 60% of sales came from US market. In previous year (2023), global bispecific antibodies sales surpassed USD 8 Billion.

Read More


Emerging CD70 Antibodies Clinical Trials Landscape

Release Date: 14 May 2024

In the realm of cancer treatment, the pursuit of new therapies is imperative to combat the relentless nature of the disease and address the limitations of current options. Existing treatments often carry debilitating side...

Read More


Blincyto Blinatumomab Sales Up 48% In 2023

Release Date: 29 February 2024

Download Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report:

 

Read More


Bispecific Antibodies Market Size Forecast USD 40 Billion By 2029

Release Date: 29 February 2024

With 12 Approved Bispecific Antibodies The Market Sales Surpassed USD 8 Billion In 2023 Says Kuick Research In Recent Published Report

 

Read More


Lunsumio Mosunetuzumab Sales Surpassed USD 65 Million In 2023

Release Date: 29 February 2024

In the ever-evolving landscape of cancer therapeutics, Roche has once again emerged as a pioneer with the late-2022 approval of Lunsumio, the third bispecific antibody in its groundbreaking portfolio, for the treatment of...

Read More


Vabysmo Faricimab Sales Surpassed USD 2 Billion In 2023

Release Date: 29 February 2024

Vabysmo, one of the flagship drugs produced by Genentech, a Roche company, has emerged as a major therapy in the field of bispecific antibodies and the pharmaceutical landscape, with extraordinary sales figures and market...

Read More


Global Bispecific Antibodies Market Size Market Forecast 2029

Release Date: 15 February 2024

Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights:

 

  • Read More


    Bicycle Toxin Conjugates Clinical Trials Bicycle Toxin Conjugate Research Bicycle Therapeutics Clinical Pipeline Report Insight

    Release Date: 07 February 2024

    Bicycle toxin conjugates are a promising advancement in targeted cancer treatment. They use bicyclic peptides to deliver toxic payloads to cancer cells. This method seeks to address the limitations of current targeted medicines, such as antibody-drug...

    Read More


    CD70 Targeted Therapies In Cancer

    Release Date: 25 January 2024

    The attention of stakeholders in the dynamic landscape of cancer therapy is rapidly turning to CD70-targeted treatments as a possible avenue for innovative intervention. CD70, a protein seen in many malignancies, has piqu...

    Read More


    Cancer Antibody Combination Therapy

    Release Date: 24 January 2024

     

    Global Cancer Antibody Combinations Market Opportunity and Clinical Trials Insight 2028 Report Findings and Highlights:

    Read More


    DLL3 Delta Like Ligand 3 As Emerging Target In Cancer Therapy

    Release Date: 23 January 2024

    In the relentless pursuit of effective cancer therapies, the need for novel approaches has become increasingly evident. As conventional treatments face limitations, the emergence of Delta-like ligand 3 (DLL3) as a target in the developme...

    Read More


    Combination Immunotherapy As Targeted therapy In Cancer

    Release Date: 05 October 2023

    The introduction of immunotherapies has resulted in a paradigm change in disease management in recent years. Harnessing the immune system’s power to attack diseases like cancer, has been a game changer. However, upo...

    Read More


    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

Need custom market research solution? We can help you with that too.